Recent Updates
Recently added Catalysts
ELTX Positive Sentiment Score: 75/100

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Monday, December 4, 2023 1 min read
Key Takeaway: Elicio Therapeutics, a clinical-stage biotech company focused on immunotherapies for cancer, has announced that CEO Robert Connelly will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company's innovative research includes novel immunotherapies aimed at enhancing immune responses in lymph nodes. A live webcast of the presentation will be available in the Investors section of their website and will remain accessible on-demand for 90 days.

Market Sentiment Analysis

POSITIVE FACTORS

  • Elicio Therapeutics is advancing immunotherapy innovations in cancer treatment.
  • The upcoming presentation at a significant conference provides a platform to showcase their research.
  • The live webcast will enable broad access to their findings for investors and stakeholders.

Full Press Release Details

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET.
A live webcast of the presentation will be accessible under “Events” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
LifeSci Communications
kpoliti@lifescicomms.com
Investor Relations Contact

Frequently Asked Questions

When is Elicio Therapeutics' presentation scheduled?

The presentation is on December 6, 2023, at 10:30 AM ET.

Where can I watch Elicio's presentation?

You can watch it live on Elicio’s website under the Events section.

What type of therapies is Elicio developing?

Elicio is developing novel immunotherapies for cancer treatment.

What is the goal of Elicio's immunotherapies?

Their aim is to target lymph nodes to enhance immune response.

How long will the presentation be available on-demand?

The presentation will be available on-demand for 90 days.

Tags: ELTX Viatris Investor Conferences Healthcare Elicio Therapeutics immunotherapies cancer treatment H.C. Wainwright
Last updated: Dec 4, 2023